Cargando…

Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases

GPBAR1, a transmembrane G protein-coupled receptor for bile acids, is widely expressed in multiple tissues in humans and rodents. In recent years, GPBAR1 has been thought to play an important role in bile homeostasis, metabolism and inflammation. This review specifically focuses on the function of G...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fangling, Xiao, Xiaolin, Li, Yong, Wu, Hefei, Deng, Xinyu, Jiang, Yinxiao, Zhang, Wenwen, Wang, Jian, Ma, Xiao, Zhao, Yanling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793736/
https://www.ncbi.nlm.nih.gov/pubmed/35095513
http://dx.doi.org/10.3389/fphar.2021.805269
_version_ 1784640667674214400
author Zhang, Fangling
Xiao, Xiaolin
Li, Yong
Wu, Hefei
Deng, Xinyu
Jiang, Yinxiao
Zhang, Wenwen
Wang, Jian
Ma, Xiao
Zhao, Yanling
author_facet Zhang, Fangling
Xiao, Xiaolin
Li, Yong
Wu, Hefei
Deng, Xinyu
Jiang, Yinxiao
Zhang, Wenwen
Wang, Jian
Ma, Xiao
Zhao, Yanling
author_sort Zhang, Fangling
collection PubMed
description GPBAR1, a transmembrane G protein-coupled receptor for bile acids, is widely expressed in multiple tissues in humans and rodents. In recent years, GPBAR1 has been thought to play an important role in bile homeostasis, metabolism and inflammation. This review specifically focuses on the function of GPBAR1 in cholestatic liver disease and summarizes the various pathways through which GPBAR1 acts in cholestatic models. GPBAR1 mainly regulates cholestasis in a holistic system of liver-gallbladder-gut formation. In the state of cholestasis, the activation of GPBAR1 could regulate liver inflammation, induce cholangiocyte regeneration to maintain the integrity of the biliary tree, control the hydrophobicity of the bile acid pool and promote the secretion of bile HCO(3) (−). All these functions of GPBAR1 might be clear ways to protect against cholestatic diseases and liver injury. However, the characteristic of GPBAR1-mediated proliferation increases the risk of proliferation of cholangiocarcinoma in malignant transformed cholangiocytes. This dichotomous function of GPBAR1 limits its use in cholestasis. During disease treatment, simultaneous activation of GPBAR1 and FXR receptors often results in improved outcomes, and this strategy may become a crucial direction in the development of bile acid-activated receptors in the future.
format Online
Article
Text
id pubmed-8793736
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87937362022-01-28 Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases Zhang, Fangling Xiao, Xiaolin Li, Yong Wu, Hefei Deng, Xinyu Jiang, Yinxiao Zhang, Wenwen Wang, Jian Ma, Xiao Zhao, Yanling Front Pharmacol Pharmacology GPBAR1, a transmembrane G protein-coupled receptor for bile acids, is widely expressed in multiple tissues in humans and rodents. In recent years, GPBAR1 has been thought to play an important role in bile homeostasis, metabolism and inflammation. This review specifically focuses on the function of GPBAR1 in cholestatic liver disease and summarizes the various pathways through which GPBAR1 acts in cholestatic models. GPBAR1 mainly regulates cholestasis in a holistic system of liver-gallbladder-gut formation. In the state of cholestasis, the activation of GPBAR1 could regulate liver inflammation, induce cholangiocyte regeneration to maintain the integrity of the biliary tree, control the hydrophobicity of the bile acid pool and promote the secretion of bile HCO(3) (−). All these functions of GPBAR1 might be clear ways to protect against cholestatic diseases and liver injury. However, the characteristic of GPBAR1-mediated proliferation increases the risk of proliferation of cholangiocarcinoma in malignant transformed cholangiocytes. This dichotomous function of GPBAR1 limits its use in cholestasis. During disease treatment, simultaneous activation of GPBAR1 and FXR receptors often results in improved outcomes, and this strategy may become a crucial direction in the development of bile acid-activated receptors in the future. Frontiers Media S.A. 2022-01-13 /pmc/articles/PMC8793736/ /pubmed/35095513 http://dx.doi.org/10.3389/fphar.2021.805269 Text en Copyright © 2022 Zhang, Xiao, Li, Wu, Deng, Jiang, Zhang, Wang, Ma and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Fangling
Xiao, Xiaolin
Li, Yong
Wu, Hefei
Deng, Xinyu
Jiang, Yinxiao
Zhang, Wenwen
Wang, Jian
Ma, Xiao
Zhao, Yanling
Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
title Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
title_full Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
title_fullStr Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
title_full_unstemmed Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
title_short Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases
title_sort therapeutic opportunities of gpbar1 in cholestatic diseases
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793736/
https://www.ncbi.nlm.nih.gov/pubmed/35095513
http://dx.doi.org/10.3389/fphar.2021.805269
work_keys_str_mv AT zhangfangling therapeuticopportunitiesofgpbar1incholestaticdiseases
AT xiaoxiaolin therapeuticopportunitiesofgpbar1incholestaticdiseases
AT liyong therapeuticopportunitiesofgpbar1incholestaticdiseases
AT wuhefei therapeuticopportunitiesofgpbar1incholestaticdiseases
AT dengxinyu therapeuticopportunitiesofgpbar1incholestaticdiseases
AT jiangyinxiao therapeuticopportunitiesofgpbar1incholestaticdiseases
AT zhangwenwen therapeuticopportunitiesofgpbar1incholestaticdiseases
AT wangjian therapeuticopportunitiesofgpbar1incholestaticdiseases
AT maxiao therapeuticopportunitiesofgpbar1incholestaticdiseases
AT zhaoyanling therapeuticopportunitiesofgpbar1incholestaticdiseases